The mTOR gene in humans produces the protein known as mTOR (mammalian target of rapamycin). A serine/threonine protein kinase called mTOR controls transcription, protein synthesis, cell motility, growth, and proliferation in living things. The phosphatidylinositol 3-kinase-related kinase protein family includes mTOR. Growth factors and amino acids are just two examples of the input from upstream pathways that mTOR integrates.Additionally, mTOR detects cellular energy, oxygen, and nutrient levels. In human diseases like diabetes, obesity, depression, and some cancers, the mTOR pathway is dysregulated. By collaborating with its intracellular receptor FKBP12, rapamycin inhibits mTOR. The mTOR FKBP12-Rapamycin Binding (FRB) domain is directly contacted by the FKBP12-rapamycin complex, which inhibits mTOR activity.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V70240 | (32-Carbonyl)-RMC-5552 | 2382768-55-8 | (32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. | |
V70255 | 10-Hydroxy-2-decenoic acid (10-HDA) | 765-01-5 | 10-Hydroxy-2-decenoic acid (10-HDA) is the main lipid component of royal jelly produced by bees. | |
V9496 | 3BDO | 890405-51-3 | 3BDO is a butyrolactone analog which acts as amTOR activator, ittargets FKBP1A and activate the mTOR signaling pathway. | |
V0177 | AZD8055 | 1009298-09-2 | AZD8055 is a novel, potent selective, and orally bioavailableATP-competitive mTOR (mammalian target of rapamycin) inhibitor with potential anticancer activity. | |
V70245 | CC214-1 | 1021920-32-0 | CC214-1 is a potentially effective mTOR inhibitor that can induce autophagy with IC50 of 0.002 μM. | |
V19634 | Desmethyl-VS-5584 | 1246535-95-4 | Desmethyl-VS-5584 is a dimethyl analog of VS-5584, a potent and specific mTOR/PI3K dual (bifunctional) inhibitor (antagonist) with a pyridine[2,3-d]pyrimidine structure. | |
V87900 | Desmethyl-VS-5584 hydrochloride | Desmethyl-VS-5584 hydrochloride is a dimethyl analog of VS-5584, a potent and selective dual mTOR/PI3K inhibitor, with a pyridine[2,3-d]pyrimidine structure. | ||
V70247 | Dihydroevocarpine | 15266-35-0 | Dihydroevocarpine induces acute myeloid leukemia cell toxicity/cytotoxicity by inhibiting mTORC1/2 activity. | |
V86185 | DNA-PK-IN-11 | 1360628-91-6 | ||
V85069 | DNA-PK-IN-12 | 2792146-91-7 | ||
V0205 | GDC-0349 (RG7603) | 1207360-89-1 | GDC-0349(also known asRG-7603) is a novel, potent,orally bioavailable and selective ATP-competitive inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity. | |
V86091 | GNE-555 | 1428902-71-9 | ||
V0179 | KU-0063794 | 938440-64-3 | KU-0063794 is a novel, potent, cell permeable and selective inhibitor of mTOR (mammalian target of rapamycin) with potential anticancer activity. | |
V2271 | L-LEUCINE-13C6 | 201740-84-3 | L-Leucine-13C6 is 13C (carbon 13) labeled L-Leucine. | |
V15518 | L-Leucine-1-13C | 74292-94-7 | L-Leucine-13C is a 13C (carbon 13)-labeled L-Leucine. | |
V87905 | LGB321 | 1210417-75-6 | LGB321 is an inhibitor of PIM2-dependent multiple myeloma cell lines, effectively inhibiting proliferation and key signaling pathways (such as mTOR-C1) and phosphorylation of BAD. | |
V84608 | LGB321 monohydrochloride | 1469925-36-7 | ||
V70237 | MHY-1685 | 27406-31-1 | MHY-1685 is a novel mTOR inhibitor that offers the opportunity to improve hCSC-based myocardial regeneration. | |
V0209 | MHY1485 | 326914-06-1 | MHY1485 is a novel, potent andcell-permeable activator of mTOR(mammalian target of rapamycin) and an inhibitor of autophagy that suppress the fusion between autophagosomes and lysosomes. | |
V70235 | MTI-31 (LXI-15029) | 1567915-38-1 | MTI-31 (LXI-15029) is a potent, orally bioactive, and selective inhibitor of mTORC1 and mTORC2. |